ARTICLE | Clinical News
WF10: Phase II data
February 9, 2015 8:00 AM UTC
Top-line data from a 16-week, double-blind, German Phase II trial in 179 patients with refractory allergic rhinitis showed that once-daily IV WF10 for 5 days missed the primary endpoint of reducing TN...